MedTrace Logo

Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult Volunteers

NCT02071758 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2016-02-23

No results posted yet for this study

Summary

The purpose of this study is to compare the safety, tolerability, and immunogenicity in healthy adult subjects of an investigational vaccine being developed for the prevention of visceral leishmaniasis.

Conditions

  • Visceral Leishmaniasis

Interventions

BIOLOGICAL

LEISH-F3 + SLA-SE

BIOLOGICAL

LEISH-F3 + GLA-SE

Sponsors & Collaborators

  • Bill and Melinda Gates Foundation

    collaborator OTHER

  • Access to Advanced Health Institute (AAHI)

    lead OTHER

Principal Investigators

  • Anna Marie Beckmann, PhD · Access to Advanced Health Institute (AAHI)

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02071758 on ClinicalTrials.gov